Abner Herrman & Brock
REGN icon

Abner Herrman & Brock’s Regeneron Pharmaceuticals REGN Stock Holding History

Abner Herrman & Brock’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$422K Hold
557
– – 0.04% 79
2026
Q2 		$347K Hold
557
– – 0.03% 84
2026
Q1 		$430K Hold
557
– – 0.05% 73
2025
Q4 		$430K Hold
557
– – 0.04% 76
2025
Q3 		$313K Buy
+557
New +$315K 0.03% 92

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Abner Herrman & Brock's REGN Position: Q3 2026 in Review

Abner Herrman & Brock held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 557 shares worth $422K. The position accounts for 0.04% of the portfolio, ranked #79.

Abner Herrman & Brock first reported a position in REGN in Q3 2025 and has held it in 5 quarters since. The position peaked at $430K in Q1 2026. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Abner Herrman & Brock held 557 shares of Regeneron Pharmaceuticals worth $422K as of Q3 2026.
  • Abner Herrman & Brock left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.04% of Abner Herrman & Brock's portfolio in Q3 2026, its #79 holding.
  • Abner Herrman & Brock first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Abner Herrman & Brock's Regeneron Pharmaceuticals position peaked at $430K in Q1 2026.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Abner Herrman & Brock's 13F filing for Q3 2026, filed 20 Oct 2026.